Can the company possibly live up to its lofty market valuation?
News & Analysis: Twist Bioscience Corporation
The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.
TWST earnings call for the period ending May 9, 2020.
An under-the-radar technology platform active in the fight against coronavirus and a leading electric utility are important stocks to keep an eye on this month.
The company announced a public offering of common stock.
The biggest source of uncertainty has been removed, allowing Wall Street to focus on the company's growth and financials. But investors should be careful what they wish for.
Twist will pay Agilent $22.5 million and receive a license to aspects of its technology.
TWST earnings call for the period ending December 31, 2019.
TWST earnings call for the period ending September 30, 2019.
Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.